CA
NZ
UK
AU
IND
US
…
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cytodyn is a clinical-stage biotechnology company developing leronlimab (PRO 140), a monoclonal antibody targeting the CCR5 receptor for indications that include HIV, certain cancers and immune-related conditions. Long-term growth depends on positive late-stage clinical outcomes, regulatory approvals and successful commercialization or strategic partnerships, which could support uptake in unmet-need populations. Investors may find the company attractive for its single-asset focus and potential multi-indication pathway that appears positioned to address treatment gaps.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Income before tax | 3.75M | -49.84M | -79.82M | -210.82M | -154.67M |
| Net income | 3.75M | -49.84M | -79.82M | -210.82M | -154.67M |
| Selling general administrative | 7.26M | 10.82M | 17.14M | 44.30M | 34.32M |
| Gross profit | - | 0.00M | 0.00M | 0.21M | -4.39M |
| Reconciled depreciation | 0.02M | 0.03M | 0.17M | 0.78M | 1.80M |
| Ebit | - | - | -40.58M | -145.40M | -139.66M |
| Ebitda | - | - | - | -157.59M | -133.39M |
| Non operating income net other | - | - | - | - | -35.06M |
| Operating income | 9.66M | -18.06M | -40.58M | -145.40M | -104.60M |
| Other operating expenses | - | - | - | 0.78M | 1.80M |
| Interest expense | 4.83M | 5.74M | 6.75M | 52.45M | 19.34M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.56M | 0.22M | - | - | 0.00M |
| Net interest income | -5.47M | -18.17M | -30.50M | -61.56M | -19.55M |
| Non recurring | - | - | - | - | 20.68M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.27M | -4.39M |
| Total operating expenses | -9.66M | 18.06M | 40.58M | 72.13M | 115.22M |
| Cost of revenue | - | 0.00M | 0.00M | 73.54M | - |
| Total other income expense net | -0.45M | -13.61M | -8.75M | -77.34M | -40.57M |
| Net income from continuing ops | 3.75M | -49.84M | -79.82M | -210.82M | -154.67M |
| Net income applicable to common shares | - | - | -86.74M | -210.82M | -154.67M |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Total assets | 18.05M | 11.14M | 11.29M | 29.18M | 132.08M |
| Intangible assets | - | - | - | 0.13M | 1.65M |
| Other current assets | - | - | 7.10M | 6.28M | 2.16M |
| Total liab | 114.09M | 127.89M | 120.79M | 123.58M | 153.10M |
| Total stockholder equity | -96.04M | -116.76M | -109.50M | -94.40M | -21.02M |
| Other current liab | 0.14M | 0.03M | 10.37M | 8.99M | 19.25M |
| Common stock | - | - | 0.92M | 0.72M | 0.63M |
| Capital stock | 1.25M | 1.06M | 0.92M | 0.72M | 0.63M |
| Retained earnings | -887.79M | -891.53M | -841.69M | -766.13M | -511.29M |
| Other assets | - | - | 0.09M | 17.93M | 93.48M |
| Cash | 11.90M | 3.11M | 2.54M | 4.23M | 33.94M |
| Total current liabilities | 70.52M | 84.18M | 119.80M | 123.16M | 152.55M |
| Net debt | 15.30M | 26.68M | 32.59M | 32.01M | 28.80M |
| Short term debt | - | - | - | 36.24M | 62.75M |
| Short long term debt | 27.20M | 29.79M | 34.42M | 36.24M | 62.75M |
| Property plant equipment | - | - | 0.40M | 0.07M | 0.13M |
| Total current assets | 17.88M | 10.81M | 10.80M | 10.52M | 129.58M |
| Net tangible assets | - | - | -109.50M | -94.53M | -22.67M |
| Long term debt | - | - | 0.71M | - | - |
| Inventory | - | - | - | 17.93M | 93.48M |
| Accounts payable | 14.69M | 29.56M | 62.73M | 81.90M | 73.15M |
| Common stock total equity | - | - | - | 0.72M | 0.63M |
| Retained earnings total equity | - | - | - | -766.13M | -511.29M |
| Non currrent assets other | 0.17M | 0.32M | 0.49M | 0.54M | 0.71M |
| Non current assets total | 0.17M | 0.32M | 0.49M | 0.74M | 2.50M |
| Capital lease obligations | 0.14M | 0.28M | 0.28M | 0.56M | 0.73M |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Investments | 0.00M | 0.00M | 0.00M | 0.00M | -0.12M |
| Change to liabilities | - | - | -3.10M | -2.71M | 53.01M |
| Total cashflows from investing activities | - | - | - | - | -0.12M |
| Net borrowings | -0.71M | 2.01M | 0.90M | 0.90M | 99.05M |
| Total cash from financing activities | 10.85M | 11.75M | 29.93M | 48.01M | 137.35M |
| Change to operating activities | - | - | 1.90M | -4.12M | 1.23M |
| Net income | 3.75M | -49.84M | -79.82M | -210.82M | -154.67M |
| Change in cash | 2.09M | 0.77M | 4.82M | -29.71M | 19.65M |
| Begin period cash flow | 9.81M | 9.05M | 4.23M | 33.94M | 14.29M |
| End period cash flow | 11.90M | 9.81M | 9.05M | 4.23M | 33.94M |
| Total cash from operating activities | -8.77M | -10.98M | -25.11M | -77.72M | -117.57M |
| Issuance of capital stock | 0.00M | 9.14M | 25.79M | 41.20M | 1.00M |
| Depreciation | 0.02M | 0.03M | 0.17M | 3.83M | 5.45M |
| Dividends paid | - | - | - | 0.00M | 0.24M |
| Change to inventory | - | - | 0.00M | 2.06M | -74.33M |
| Sale purchase of stock | - | - | - | 42.62M | 22.27M |
| Other cashflows from financing activities | - | - | 2.81M | 5.39M | 16.27M |
| Change to netincome | - | - | 43.86M | 79.73M | 51.74M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.12M |
| Cash flows other operating | - | - | - | 50.20M | 1.23M |
| Cash and cash equivalents changes | - | - | - | -29.71M | 19.65M |
| Change in working capital | -16.17M | 11.66M | -1.20M | -4.78M | -20.09M |
| Stock based compensation | 1.61M | 2.42M | 4.28M | 6.24M | 10.43M |
| Other non cash items | - | 4.47M | 16.76M | 57.37M | 15.02M |
| Free cash flow | -8.77M | -10.98M | -25.11M | -77.72M | -117.69M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CYDY Cytodyn Inc |
-0.01 2.22% |
0.22 | - | 10.81 | 761.84 | 1066.03 | 1010.08 | 40.35 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
| Name | Title | Year Born |
|---|---|---|
| Mr. Antonio Migliarese CPA | CFO, Treasurer & Sec. | 1983 |
| Mr. Cyrus Arman M.B.A., Ph.D. | Pres | 1981 |
| Dr. Bernie Cunningham P.M.P., Ph.D. | VP of Operations | NA |
| Mr. George Bitar | Head of Quality & Exec. Director | NA |
| Dr. Kush Dhody | Sr. VP of Clinical Operations | NA |
| Dr. Denis R. Burger | Scientific Consultant | 1944 |
| Ms. Cristina De Leon | Investors | NA |
| Dr. Jacob P. Lalezari M.D. | Chief Executive Officer | 1960 |
| Mr. Tyler Blok | Chief Legal Officer & Corporate Secretary | 1987 |
| Dr. Bernie Cunningham P.M.P., Ph.D. | Vice President of Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...